Skip to main content
. 2016 Dec 27;8(6):9996–10006. doi: 10.18632/oncotarget.14310

Figure 2.

Figure 2

Acceptability curves comparing the cost-effectiveness of four competing strategies with the PAP A. or without the PAP B. QALY: quality-adjusted life-year. PC: pemetrexed plus cisplatin.